Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
MYSM1 Deficiency Bone Marrow Failure - Insights into Disease Mechanisms from an iPSC Model
FY 2021-22
Summary
Hematopoiesis
is the process that produces blood cells from bone marrow resident
hematopoietic stem and progenitor cells (HSPCs). Careful regulation of
this process is necessary for normal blood and immune system function, and
many proteins and other factors are involved in maintaining this
regulation. MYSM1 is a histone H2A K119-deubiquitinase that plays an
important role in maintaining HSPCs and hematopoiesis in humans.
Dysfunction of this gene leads to hematopoietic pathology and skeletal
abnormalities, similar to ribosomopathy disorders like Diamond-Blackfan
anemia and Shwachman-Diamond syndrome. Importantly, our team showed that
in mouse HSPCs MYSM1 deficiency results in reduced expression of genes
encoding ribosomal proteins, reduced protein synthesis, and induction of
p53 dependent stress response. Based on these findings, we hypothesize
that MYSM1 deficiency disorder in humans is a form ribosomopathy - a
disease caused by dysfunctions in ribosome assembly and protein synthesis.
However, to date, all work to explore this hypothesis has been based in
mouse models and the mechanisms have yet to be validated in a human
system. Currently, we have established a human experimental system to
study MYSM1 function, with isogenic iPSC lines: wild type, heterozygous,
and homozygous for the MYSM1-p.S290* patient mutation, through CRISPR/Cas9
gene-editing. In my research project, the characterization of these iPSC
models promises novel insight into the mechanisms of MYSM1 deficiency
syndrome in human, which in the long term may facilitate the design of
clinical therapies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
481321
Name
Shaban Dania
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
MYSM1 Deficiency Bone Marrow Failure - Insights into Disease Mechanisms from an iPSC Model
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Marrow Failure; Hematopoiesis; Hematopoietic Stem And Progenitor Cells; Induced Pluripotent Stem Cells; Primary Immunodeficiency; Regulation Of Gene Expression
Abstract
<html>
<head>
</head>
<body>
<span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none"><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px">Hematopoiesis
is the process that produces blood cells from bone marrow resident
hematopoietic stem and progenitor cells (HSPCs). Careful regulation of
this process is necessary for normal blood and immune system function, and
many proteins and other factors are involved in maintaining this
regulation. MYSM1 is a histone H2A K119-deubiquitinase that plays an
important role in maintaining HSPCs and hematopoiesis in humans.
Dysfunction of this gene leads to hematopoietic pathology and skeletal
abnormalities, similar to ribosomopathy disorders like Diamond-Blackfan
anemia and Shwachman-Diamond syndrome. Importantly, our team showed that
in mouse HSPCs MYSM1 deficiency results in reduced expression of genes
encoding ribosomal proteins, reduced protein synthesis, and induction of
p53 dependent stress response. Based on these findings, we hypothesize
that MYSM1 deficiency disorder in humans is a form ribosomopathy - a
disease caused by dysfunctions in ribosome assembly and protein synthesis.
However, to date, all work to explore this hypothesis has been based in
mouse models and the mechanisms have yet to be validated in a human
system. Currently, we have established a human experimental system to
study MYSM1 function, with isogenic iPSC lines: wild type, heterozygous,
and homozygous for the MYSM1-p.S290* patient mutation, through CRISPR/Cas9
gene-editing. In my research project, the characterization of these iPSC
models promises novel insight into the mechanisms of MYSM1 deficiency
syndrome in human, which in the long term may facilitate the design of
clinical therapies.</font></span>
</body>
</html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shaban, Dania
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~